glp-1 compounding crackdown news october 2025 The FDA announced plans to take action against non-FDA-approved receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the I'm stuck in the gray

Non-alcoholic fatty liver disease (NAFLD) now affects up to a quarter of the global population, tightly linked to obesity, insulin resistance, and type 2 diabetes

We will explore dietary changes, lifestyle modifications, and targeted gut-supportive techniques to help you stay on track with your GLP-1 weight management plan without feeling all pukey on a daily basis

We know that there are over a dozen cancers that are associated with obesity and breast cancer is one of them

Given trial heterogeneity (doses, agents, durations), individualization, monitoring, lifestyle support, and collaboration with hepatology are key